Patent ID: 8389247
Filing Date: 2013-03-05
Classification: C12Q

Abstract:
1. A method of identifying markers in an individual correlated with the individual's likelihood developing increased body mass associated with the use of olanzapine, comprising: assaying genetic material from the individual for the presence of at least one positive coefficient marker and at least one negative coefficient marker to produce a physiotype for the individual, wherein the positive coefficient marker is rs7412 corresponding to SEQ ID NO. 297 and the negative coefficient marker is rs5092 corresponding to SEQ ID NO. 22, wherein at least one positive coefficient marker and at least one negative coefficient marker are oppositely associated with the likelihood of developing increased body mass associated with the use of olanzapine in the individual, wherein the presence of a variant allele at position 22 of SEQ ID NO: 297 is associated with a likelihood of an increase in body mass associated with the use of olanzapine in the human individual and the presence of a variant allele at position 22 of SEQ ID NO: 22 is associated with a likelihood of a decrease in body mass associated with the use of olanzapine in the human individual, and wherein position 22 of SEQ ID NO: 22 and position 22 of SEQ ID NO: 297 each include one variant allele and one wild type allele.